Abstracts Archive - Page 544 of 1683 - ATC Abstracts

2020 American Transplant Congress
Coagulation and Cd46 Transgene Modification in Neonatal Porcine Islet Xenotransplantation
M. Song, Z. Fitch, K. Samy, Q. Gao, R. P. Davis, F. Leopard, R. Schmitz, N. Huffman, G. Devi, B. Collins, A. D. Kirk
Surgery, Duke University, Durham, NC
*Purpose: Vascular thrombosis is a potential cause for early intraportal xeno-islet loss. To better understand the relationship between coagulation and inflammation in early xeno-islet transplantation,…
2020 American Transplant Congress
In-Vivo Application of Ides (Imlifidase) in Nonhuman Primates Results in Xenoreactive Desensitization: A Novel Anti-Humoral Therapy
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. Breeden¹, S. C. Kim¹, A. J. Tector², A. Robertson³, C. Kjellman³, A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL, ³HANSA Biopharma, Lund, Sweden
*Purpose: Antibody-mediated rejection is a formidable barrier to xenograft survival. A novel anti-humoral IdeS therapy, which cleaves serum IgG, represents a promising therapy to reduce…
2020 American Transplant Congress
Molecular Features of HLA Mismatches as Predictors of De Novo DSA Development: A Single Center Experience
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Several molecular features (MoFs) of HLA mismatches (MMs) are currently used to predict the development of de novo donor-specific anti-HLA antibodies (dnDSA). The purpose…
2020 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
R. Michael, B. Mierzejewska, D. Bekbolsynov, J. Ortiz, O. Ekwenna, S. Stepkowski
University of Toledo, Toledo, OH
*Purpose: The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…
2020 American Transplant Congress
Low HLA Class I Epitope Mismatch Associated with Improved Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplantation
J. M. Ladowski, M. Romine, D. Kloda, C. Young, J. Locke, V. Hauptfeld-Dolejsek, J. Houp
University of Alabama-Birmingham, Birmingham, AL
*Purpose: Antibody-mediated rejection remains the principal cause of allotransplant graft failure. Human leukocyte antigen (HLA) matching between donor and recipients significantly reduces the risk of…
2020 American Transplant Congress
A Simple HLA Class II Matching Strategy for the Prediction of De Novo Donor-Specific HLA Antibodies
L. G. Hidalgo¹, I. A. Martinez Juarez², L. Morales-Buenrostro³, S. Shojai⁴, P. Campbell⁴
¹Surgery, University of Wisconsin - Madison, Madison, WI, ²Nephrology, Hospital Angeles Pedregal, Mexico City, Mexico, ³Nephrology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: In kidney transplantation, degree of HLA Class II mismatch (MM) between donor and recipient drives the risk to develop de novo DSA (dnDSA). New…
2020 American Transplant Congress
Calculated Panel Reactive Antibody Values Increase for Kidney Transplant Candidates with HLA-DQA and HLA-DPB Unacceptable Antigens
E. P. Kransdorf¹, C. Murphey², M. Maiers³, L. Gragert⁴
¹Cedars-Sinai Heart Institute, Beverly Hills, CA, ²Immunogenetics Lab, Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Bioinformatics Research, Be The Match/National Marrow Donor Program, Minneapolis, MN, ⁴Department of Pathology, Tulane University School of Medicine, New Orleans, LA
*Purpose: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. CPRA includes…
2020 American Transplant Congress
Conversion to Belatacept in HIV(+) Renal Transplant Recipients
A. Santeusanio, A. Bhansali, R. Shapiro, G. De Boccardo
Mount Sinai Hospital, New York, NY
*Purpose: HIV(+) renal transplant recipients were excluded from phase III trials of belatacept, and currently there are only scattered case reports.*Methods: This was a single…
2020 American Transplant Congress
Prospective, Randomized Study of Conversion from Calcineurin Inhibitor (CNI)- to Belatacept (BELA)-Based Maintenance Immunosuppression in Renal Transplant Recipients
K. Budde¹, R. Prashar², H. Haller³, M. Rial⁴, N. Kamar⁵, A. Agarwal⁶, J. de Fijter⁷, L. Rostaing⁸, S. Berger⁹, A. Djamali¹⁰, N. Leca¹¹, L. Allamassey¹², S. Gao¹², M. Polinsky¹², F. Vincenti¹³
¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Henry Ford Hospital, Detroit, MI, ³The Hannover Medical School, Hannover, Germany, ⁴Instituto de Nefrologia, Nephrology SA, Buenos Aires, Argentina, ⁵University of Toulouse, Toulouse, France, ⁶UVA Health, Charlottesville, VA, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Université Grenoble Alpes, Saint-Martin-d'Hères, France, ⁹University Medical Centre Groningen, Groningen, Netherlands, ¹⁰University of Wisconsin, Madison, WI, ¹¹UW Medical Center, Seattle, WA, ¹²Bristol-Myers Squibb, Princeton, NJ, ¹³University of California, San Francisco, San Francisco, CA
*Purpose: CNIs are associated with adverse systemic and nephrotoxic effects that negatively impact long-term patient and graft survival. In a phase 2 study, switching renal…
2020 American Transplant Congress
Belatacept Conversion: Are Patients BENEFIT-ing
R. Crew, S. Mohan, S. S. Patel
Columbia University Irving Medical Center, New York, NY
*Purpose: Belatacept is increasingly used in renal transplant recipients experiencing adverse effects from calcineurin inhibitors(CNI) despite limited medium- and long- term data on safety and…